文献速递肿瘤 PET/CT核素与放射性配体治疗

161Tb-DOTATOC首次人体应用可行性研究

First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC.
PubMed 文献 · J Nucl Med · 2021-02-05

本研究将161Tb标记的DOTATOC用于两名转移性肿瘤患者,分别给药596和1300 MBq,通过平面γ显像和SPECT/CT评估生物分布与显像质量。结果显示标记纯度高、显像质量好、可显示骨和肝内小转移灶,且未报告相关不良事件,证明了161Tb临床显像可行性。

要点

  • 161Tb-DOTATOC标记纯度高,适用于患者给药。
  • 平面γ显像和SPECT/CT可显示骨和肝内小转移灶。
  • 给药后耐受良好,未报告相关不良事件。

核心结论

  • 注射相对低活度的161Tb-DOTATOC后,平面γ显像和SPECT/CT可显示甚至小转移灶,证明临床显像可行。

研究设计与样本

  • 两例患者分别接受596和1300 MBq的161Tb-DOTATOC,进行多日全身平面γ显像用于剂量学计算,并用新建立方案重建SPECT/CT进行视觉分析。

主要发现

  • 平面图像和剂量学显示161Tb-DOTATOC在肝、肾、脾和膀胱中呈预期的时间依赖性生物分布。
  • SPECT/CT图像质量高,可显示骨和肝内小转移灶。
  • 给药后患者耐受良好,未报告相关不良事件。

关键数值与推荐

  • 35岁男性转移性高分化无功能恶性副神经节瘤患者接受596 MBq的161Tb-DOTATOC。
  • 70岁男性转移性功能性胰腺尾部神经内分泌肿瘤患者接受1300 MBq的161Tb-DOTATOC。

临床怎么用

  • 161Tb-DOTATOC可用于转移性神经内分泌肿瘤等生长抑素受体阳性病灶的显像评估。

局限性

  • 仅两例患者,样本量小,可行性结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

161Tb has decay properties similar to those of 177Lu but, additionally, emits a substantial number of conversion and Auger electrons. The aim of this study was to apply 161Tb in a clinical setting and to investigate the feasibility of visualizing the physiologic and tumor biodistributions of 161Tb-DOTATOC. Methods:161Tb was shipped from Paul Scherrer Institute, Villigen-PSI, Switzerland, to Zentralklinik Bad Berka, Bad Berka, Germany, where it was used for the radiolabeling of DOTATOC. In 2 separate studies, 596 and 1,300 MBq of 161Tb-DOTATOC were administered to a 35-y-old male patient with a metastatic, well-differentiated, nonfunctional malignant paraganglioma and a 70-y-old male patient with a metastatic, functional neuroendocrine neoplasm of the pancreatic tail, respectively. Whole-body planar γ-scintigraphy images were acquired over a period of several days for dosimetry calculations. SPECT/CT images were reconstructed using a recently established protocol and visually analyzed. Patients were observed for adverse events after the application of 161Tb-DOTATOC. Results: The radiolabeling of DOTATOC with 161Tb was readily achieved with a high radiochemical purity suitable for patient application. Planar images and dosimetry provided the expected time-dependent biodistribution of 161Tb-DOTATOC in the liver, kidneys, spleen, and urinary bladder. SPECT/CT images were of high quality and visualized even small metastases in bones and liver. The application of 161Tb-DOTATOC was well tolerated, and no related adverse events were reported. Conclusion: This study demonstrated the feasibility of imaging even small metastases after the injection of relatively low activities of 161Tb-DOTATOC using γ-scintigraphy and SPECT/CT. On the basis of this essential first step in translating 161Tb to clinics, further efforts will be directed toward the application of 161Tb for therapeutic purposes.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Baum RP, Singh A, Kulkarni HR, et al. First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC. J Nucl Med. 2021. PMID: 33547209. doi:10.2967/jnumed.120.258376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。